ReviewPediatric nephrology (Berlin, Germany)2008
Pathogenesis and treatment of peritoneal membrane failure.
Review in Pediatric nephrology (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Sterile inflammation of peritoneal membrane caused by peritoneal dialysis: focus on the communication between immune cells and peritoneal stroma.Frontiers in immunology · 2024Review
- Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling.Frontiers in pharmacology · 2022Article
- Adhesions and Anti-Adhesion Systems Highlights.Facts, views & vision in ObGyn · 2019Review
- Transcriptome analysis of signaling pathways of human peritoneal mesothelial cells in response to different osmotic agents in a peritoneal dialysis solution.BMC nephrology · 2019Article
- Human umbilical cord mesenchymal stem cells facilitate the up-regulation of miR-153-3p, whereby attenuating MGO-induced peritoneal fibrosis in rats.Journal of cellular and molecular medicine · 2018Article
- Pharmacological inhibition of heparin-binding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model.Clinical and experimental nephrology · 2018Article
- Hyperbranched polyglycerol is superior to glucose for long-term preservation of peritoneal membrane in a rat model of chronic peritoneal dialysis.Journal of translational medicine · 2016Article
- Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.Journal of the American Society of Nephrology : JASN · 2016Article
- Suramin inhibits the development and progression of peritoneal fibrosis.The Journal of pharmacology and experimental therapeutics · 2014Article
- Strategies for the preservation of residual renal function in pediatric dialysis patients.Pediatric nephrology (Berlin, Germany) · 2014Review
- Residual renal function in children treated with chronic peritoneal dialysis.TheScientificWorldJournal · 2013Review
- Can sonographic peritoneal thickness be used to follow pediatric patients on peritoneal dialysis?Pediatric nephrology (Berlin, Germany) · 2013Article
- Article
- Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.Pediatric nephrology (Berlin, Germany) · 2011Article
- Peritoneal morphologic changes in a peritoneal dialysis rat model correlate with angiopoietin/Tie-2.Pediatric nephrology (Berlin, Germany) · 2009Article
- The Role of Tyrosine Kinase Receptors in Peritoneal Fibrosis.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisReview
- Hyperbranched polyglycerol is an efficacious and biocompatible novel osmotic agent in a rodent model of peritoneal dialysis.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisArticle
- Peritoneal fibrosis and high transport are induced in mildly pre-injured peritoneum by 3,4-dideoxyglucosone-3-ene in mice.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis (PD) is a viable treatment option for end stage renal disease (ESRD) patients worldwide. PD may provide a survival advantages over hemodialysis (HD) in the early years of treatment. However, the benefits of PD are short-lived, as peritoneal membrane failure ensues in many patients, owing mainly to structural and functional changes in the peritoneal membrane from the use of conventional bio-incompatible PD solutions, which are hyperosmolar, acidic, have lactate buffer and contain high concentrations of glucose and glucose degradation products (GDPs). Current data suggest that chronic exposure of the peritoneum to contemporary PD fluids provokes activation of various inflammatory, fibrogenic and angiogenic cytokines, interplay of which leads to progressive peritoneal fibrosis, vasculopathy and neoangiogenesis. There is emerging evidence that peritoneal vascular changes are mainly responsible for increased solute transport and ultrafiltration failure in long-term PD. However, the precise pathophysiologic mechanisms initiating and propagating peritoneal fibrosis and angiogenesis remain elusive. The protection of the peritoneal membrane from long-term toxic and metabolic effects of high GDP-containing, conventional, glucose-based solutions is a prime objective to improve PD outcome. Recent development of new, more biocompatible, PD solutions should help to preserve peritoneal membrane function, promote ultrafiltration, improve nutritional status and, hopefully, preserve peritoneal membrane and improve overall PD outcomes. Elucidation of molecular mechanisms involved in the cellular responses leading to peritoneal fibrosis and angiogenesis spurs new therapeutic strategies that might protect the peritoneal membrane against the consequences of longstanding PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.